Lifecore Biomedical, Inc. De (LFCR) Receivables (2011 - 2025)

Lifecore Biomedical has reported Receivables for 15 years, with the latest figure at $22.1 million in Q2 2025.

• On a quarterly basis, Receivables fell 38.41% year-over-year to $22.1 million in Q2 2025; TTM through May 2025 was $22.1 million, a 38.41% decrease from a year earlier, with the FY2025 full-year figure at $22.1 million, down 38.41% from the prior year.
• Receivables was $22.1 million for Q2 2025 at Lifecore Biomedical, down from $22.3 million in the prior quarter.
• The five-year high for Receivables was $53.6 million in Q1 2022, with the low at $20.0 million in Q3 2023.
• Average Receivables over 5 years is $33.4 million, with a median of $34.2 million recorded in 2023.
• The sharpest annual moves came in 2021 and 2022: Receivables sank 58.69% in 2021, then surged 84.59% in 2022.
• Over 5 years, Receivables stood at $40.1 million in 2021, then declined by 10.57% to $35.9 million in 2022, then sank by 37.72% to $22.3 million in 2023, then surged by 63.73% to $36.6 million in 2024, then sank by 39.47% to $22.1 million in 2025.
• The last three Receivables figures came in at $22.1 million (Q2 2025), $22.3 million (Q1 2025), and $36.6 million (Q4 2024), per Business Quant data.